Wang Yanhong, Cao Xixiang, Shan Baodong, Chen Song, Li Shengnan, Fei Sujuan, Pang Xunlei
Department of Gastroenterology, The Affiliated Hospital of Xuzhou Medical University, Huaihai West Road, Xuzhou, Jiang Su, 221004, China.
Graduate school, Xuzhou Medical University, Xuzhou, 221009, China.
J Health Popul Nutr. 2025 Jan 24;44(1):20. doi: 10.1186/s41043-025-00756-y.
This study aims to assess the serum levels of pepsinogen (PG)I, PG II, and gastrin (G17) in patients with gastric intestinal metaplasia (GIM) and evaluate their correlation with demographic characteristics.
A total of 247 normal controls (NC) and 240 patients diagnosed with GIM were enrolled in this study. All participants underwent a gastroscopy procedure followed by pathological examination for diagnosis confirmation. The expression level of PGI, PG II, and G 17 was detected by fluorescence immunochromatography and Hp infection was detected by 13-carbon breath test. The demographic characteristics of the subjects were obtained through questionnaires.
Compared to the NC group, the GIM group showed a reduction in PG II expression level [10.71(6.40,16.89) VS 9.21(6.14,14.55), p = 0.010]. GIM patients had a higher prevalence of previous Hp eradication history (14.98% VS 23.75%, p = 0.014). The low PG II group exhibited a higher incidence rate of GIM compared to the high PG II group (54.10% VS 44.44%, p = 0 0.020). In the Hp-negative(Hp-) group, there was a decrease in both PGI and PG II expression levels when compared to the Hp-positive(Hp+) group [146.73 ± 78.53 VS 125.61 ± 68.75 and 10.19(7.27, 16.58) VS 7.36(5.62,12.53), p = 0.036 and p < 0.001]. Among patients without Hp eradication history, those with low PG II levels had a higher proportion of individuals with a history of Hp eradication than those with high PG II levels (29.31% VS 3.13%, p = 0.003). Additionally, within the subgroup that underwent Hp eradication, there was a decrease in PG II expression level compared to the subgroup without Hp eradication (6.16(5.13, 7.52) VS 8.73(5.67, 13.35), p = 0.041).
The prevalence of GIM was significantly associated with low levels of PG II. There was a significant association between HP eradication history and the prevalence of GIM. Hp eradication history resulted in reduced expression levels of PG II in Hp- GIM patients.
本研究旨在评估胃肠化生（GIM）患者血清中胃蛋白酶原（PG）I、PG II和胃泌素（G17）的水平，并评估它们与人口统计学特征的相关性。
本研究共纳入247名正常对照（NC）和240名诊断为GIM的患者。所有参与者均接受胃镜检查，随后进行病理检查以确诊。采用荧光免疫层析法检测PGI、PG II和G 17的表达水平，采用13碳呼气试验检测Hp感染情况。通过问卷调查获取受试者的人口统计学特征。
与NC组相比，GIM组PG II表达水平降低[10.71(6.40,16.89) 对 9.21(6.14,14.55)，p = 0.010]。GIM患者既往Hp根除史的患病率更高（14.98% 对 23.75%，p = 0.014）。低PG II组GIM的发病率高于高PG II组（54.10% 对 44.44%，p = 0.020）。在Hp阴性（Hp-）组中，与Hp阳性（Hp+）组相比，PGI和PG II表达水平均降低[146.73 ± 78.53 对 125.61 ± 68.75以及10.19(7.27, 16.58) 对 7.36(5.62,12.53)，p = 0.036和p < 0.001]。在无Hp根除史的患者中，PG II水平低的患者有Hp根除史的比例高于PG II水平高的患者（29.31% 对 3.13%，p = 0.003）。此外，在接受Hp根除的亚组中，与未接受Hp根除的亚组相比，PG II表达水平降低（6.16(5.13, 7.52) 对 8.73(5.67, 13.35)，p = 0.041）。
GIM的患病率与低水平的PG II显著相关。Hp根除史与GIM的患病率之间存在显著关联。Hp根除史导致Hp- GIM患者PG II表达水平降低。
